Revenue Beat: BioNTech SE Beat Analyst Estimates By 24%
As you might know, BioNTech SE (NASDAQ:BNTX) just kicked off its latest quarterly results with some very strong numbers. Performance was better than the analysts expected, with revenues of €1.3b coming in24% ahead of expectations, and statutory earnings per share (EPS) of €0.73 exceeding forecasts by 16%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the 18 analysts covering BioNTech provided consensus estimates of €1.80b revenue in 2027, which would reflect a substantial 26% decline over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to €5.34. Before this latest report, the consensus had been expecting revenues of €1.80b and €5.36 per share in losses.
View our latest analysis for BioNTech
As a result there was no major change to the consensus price target of US$116, implying that the business is trading roughly in line with expectations despite ongoing losses. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values BioNTech at US$144 per share, while the most bearish prices it at US$75.95. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the BioNTech's past performance and to peers in the same industry. We would also point out that the forecast 21% annualised revenue decline to the end of 2027 is better than the historical trend, which saw revenues shrink 49% annually over the past five years Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 21% annually. So while a broad number of companies are forecast to grow, unfortunately BioNTech is expected to see its revenue affected worse than other companies in the industry.
The Bottom Line
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for BioNTech going out to 2028, and you can see them free on our platform here..
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.